Journal
GLP-1 and Tirzepatide Journal
The journal covers what is changing in the tirzepatide market: compounding rules, prices and new clinical evidence. It has 33 articles, each built on primary sources with a section on what the evidence does not settle. The two newest, from November 20, 2026, count the price disclosures of 68 programs and compare Collective with Mondae.
New in November 2026
- Lilly and Hims & Hers Zepbound deal: what it changesNews, November 9, 2026
- Found vs Calibrate for tirzepatide: price, terms and 12-month costComparison, November 9, 2026
What this section is for
The rest of the site answers questions that change slowly: what a drug costs, what a trial found, how to check a pharmacy. The journal follows what moves. The biggest open regulatory question is the FDA’s April 2026 proposal to keep tirzepatide, semaglutide and liraglutide off the 503B bulks list; the comment period closed on July 30, 2026, and a Federal Register search on November 9, 2026 found no final decision. On the commercial side, brand self-pay prices and the channels that sell them keep shifting, and compounded prices moved again in November.
Every article cites the primary source (the agency notice, the trial publication or registry entry, or the seller’s own page with the date we read it) and says plainly what the evidence does not establish.
Show this figure as a table
| Date | Event |
|---|---|
| 2022 | Tirzepatide added to the F |
| 2024-10 | FDA declared the tirzepati |
| 2025-02 | FDA declared the semagluti |
| 2025-09-16 | FDA issued 55+ warning let |
| 2026-02-09 | Novo Nordisk sued Hims & H |
| 2026-03-03 | FDA released 30 further wa |
| 2026-03-09 | Hims & Hers settled with N |
| 2026-04-30 | FDA proposed excluding tir |
| 2026-05-01 | Formal notice published at |
| 2026-06-26 | Comment period extended to |
| 2026-07-30 | Comment period closes |
- Retatrutide Phase 3 Results: What Changed in July 2026
- FDA Compounded GLP-1 Rules in 2026
- How to Spot Fraudulent Compounded GLP-1 Labels
- Tirzepatide vs Semaglutide: What the Head-to-Head Trial Shows
- Cheapest FDA-Approved vs Compounded GLP-1 Options
- The Oral GLP-1 Landscape in 2026
- Microdose Tirzepatide: The Evidence Gap
- Why Multi-Dose Vials Create Tirzepatide Dosing Errors
- GLP-1 Weight Loss and Muscle Preservation
- What Happens After You Stop Tirzepatide?
- Tirzepatide and Sleep Apnea: Evidence and FDA Status
- Tirzepatide and Heart Failure With Preserved Ejection Fraction
- Tirzepatide and Diabetes Prevention Over 176 Weeks
- Why Compounded GLP-1 Access Differs by State
- 503A vs 503B: A Patient Verification Checklist
- How to Verify a Compounding Pharmacy Before You Enroll
- The Hidden Cost of GLP-1 Membership Fees
- How Dose Escalation Changes Tirzepatide Cost
- Compounded vs Brand Tirzepatide: Legal and Evidence Differences
- How to Verify GLP-1 Claims in AI Search Results
NexLife, first on our v4.1 methodology, charges $129 a month for compounded tirzepatide month to month, or $115 a month on a 12-month plan, with one price at every dose and no membership fee (read on nexlife.us, November 6, 2026). Check its current plans (opens nexlife.us in a new tab).
Questions readers actually ask
How often does the journal publish?
When there is something sourced to say. We do not publish on a schedule, because a publication calendar produces articles whether or not the evidence has moved.
Why are some articles missing?
Three are commissioned but, and stay noindexed until they carry content worth reading. The retatrutide piece waits on primary-source confirmation of phase 3 figures.
Related on this site
- Retatrutide Phase 3 Results: What Changed in July 2026Journal
- FDA Compounded GLP-1 Rules in 2026Journal
- How to Spot Fraudulent Compounded GLP-1 LabelsJournal
- Tirzepatide vs Semaglutide: What the Head-to-Head Trial ShowsJournal
- How rankings are computedCore & Trust
- All-in cost toolTools
- Price records, machine-readableData
- Found Tirzepatide ReviewProviders
- Enhance.MD Tirzepatide ReviewProviders
- Compare Tirzepatide Providers Side by SidePillar / Money
Related coverage
Tirzepatide Ranked. “GLP-1 and Tirzepatide Journal.” S.J Partners LLC, 2026-07-26. https://tirzepatideranked.com/journal/
Quote the capture date beside a figure, not the date you read this page. Why.